CYCC [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own1.10% Shs Outstand12.31M Perf Week4.07%
Market Cap10.07M Forward P/E- EPS next Y-1.98 Insider Trans0.00% Shs Float12.08M Perf Month-27.50%
Income-19.30M PEG- EPS next Q-0.44 Inst Own33.40% Short Float / Ratio3.70% / 3.31 Perf Quarter-48.52%
Sales- P/S- EPS this Y37.40% Inst Trans28.80% Short Interest0.45M Perf Half Y-26.89%
Book/sh2.16 P/B0.40 EPS next Y-13.10% ROA-51.90% Target Price18.00 Perf Year-75.00%
Cash/sh2.05 P/C0.42 EPS next 5Y- ROE-60.50% 52W Range0.76 - 4.53 Perf YTD-77.63%
Dividend- P/FCF- EPS past 5Y9.40% ROI- 52W High-80.77% Beta1.06
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low14.16% ATR0.10
Employees12 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)38.02 Volatility10.49% 11.33%
OptionableYes Debt/Eq0.00 EPS Q/Q22.30% Profit Margin- Rel Volume1.41 Prev Close0.77
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume134.73K Price0.87
Recom1.50 SMA20-14.19% SMA50-26.79% SMA200-49.51% Volume189,660 Change13.06%
Jul-18-22Resumed Oppenheimer Outperform $17
Apr-27-20Resumed ROTH Capital Buy $24
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Show Previous Ratings
Nov-09-22 04:05PM
Nov-07-22 10:33AM
Nov-03-22 09:15AM
Oct-26-22 09:15AM
Oct-24-22 09:15AM
09:15AM Loading…
Oct-13-22 09:15AM
Sep-21-22 09:15AM
Aug-10-22 04:05PM
Aug-03-22 09:15AM
Jun-30-22 12:46PM
09:15AM
Jun-22-22 07:04AM
Jun-14-22 09:23AM
May-11-22 04:05PM
May-04-22 09:15AM
09:15AM Loading…
Apr-19-22 09:15AM
Apr-15-22 08:33AM
Apr-12-22 07:00AM
Mar-28-22 04:05PM
Mar-22-22 07:00AM
Mar-09-22 07:00AM
Feb-07-22 07:00AM
Jan-06-22 07:00AM
Dec-23-21 07:00AM
Dec-20-21 02:00AM
Dec-07-21 05:25AM
Nov-10-21 04:05PM
Nov-05-21 09:41AM
Oct-29-21 07:00AM
Oct-04-21 09:00AM
07:00AM Loading…
Sep-08-21 07:00AM
Aug-11-21 04:05PM
Aug-03-21 07:00AM
Jul-13-21 07:00AM
Jul-07-21 07:15AM
May-17-21 08:30PM
May-12-21 04:05PM
02:30PM
May-05-21 07:00AM
Mar-16-21 04:05PM
Mar-15-21 07:16AM
Mar-12-21 08:30AM
Mar-11-21 04:01PM
Feb-25-21 04:05PM
02:30PM
Feb-19-21 07:00AM
Feb-10-21 07:00AM
Feb-01-21 10:05PM
Jan-11-21 07:46AM
Dec-30-20 07:00AM
Dec-22-20 08:00AM
Dec-21-20 07:00AM
Nov-11-20 04:05PM
02:30PM
Nov-05-20 09:29AM
Oct-26-20 08:26AM
Oct-23-20 04:30PM
Oct-05-20 07:00AM
Sep-21-20 07:00AM
Aug-16-20 04:26AM
Aug-12-20 04:05PM
Aug-05-20 07:00AM
Jul-28-20 11:46AM
Jul-13-20 07:00AM
May-21-20 09:22AM
May-12-20 04:05PM
May-05-20 07:00AM
Apr-24-20 04:05PM
Apr-21-20 12:59PM
08:27AM
Apr-20-20 07:00AM
Apr-14-20 12:30PM
Mar-17-20 07:17AM
Mar-12-20 12:13AM
Feb-26-20 04:05PM
Feb-20-20 08:50AM
Feb-19-20 07:00AM
Feb-10-20 08:53AM
Feb-03-20 07:00AM
Jan-13-20 07:00AM
Jan-06-20 07:00AM
Dec-11-19 06:13AM
Dec-09-19 07:00AM
Dec-04-19 07:18AM
Nov-13-19 04:05PM
Nov-07-19 07:00AM
Nov-06-19 09:00AM
Oct-12-19 09:44AM
Sep-23-19 07:00AM
Sep-09-19 07:00AM
Sep-04-19 07:00AM
Sep-03-19 12:30PM
Aug-28-19 12:34PM
Aug-13-19 04:05PM
07:25AM
Aug-11-19 03:46PM
Aug-07-19 07:00AM
Jul-22-19 07:00AM
Jul-04-19 06:49AM
Jun-26-19 02:59PM
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.